Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Apr Applied Pharma Research SA has 1 pending office action in Biotechnology & Pharmaceuticals. The record identifies 1 distinct examiner and 1 distinct art unit. SOROUSH, LAYLA is the busiest examiner, with 1 pending matter. The profile reflects one focused examination path for the company’s pharmaceutical research subject matter.
Practitioners should direct prosecution resources to the outstanding action and prepare arguments that respond specifically to the assigned examiner’s analysis. Any amendment should be checked against the original disclosure and the intended scope of the pharmaceutical claims. With one examiner and one art unit represented, the existing file history provides the relevant context for planning the response and maintaining consistency in later prosecution steps.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044358 | DERMAL COMPOSITIONS REPLICATING THE VERNIX CASEOSA | SOROUSH, LAYLA | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044358 | DERMAL COMPOSITIONS REPLICATING THE VERNIX CASEOSA | SOROUSH, LAYLA | 27d |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044358 | DERMAL COMPOSITIONS REPLICATING THE VERNIX CASEOSA | SOROUSH, LAYLA | 1622 | §103§112 | Non-Final OA | 27d | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApr Applied Pharma Research SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla Soroush has the most, with 1 of Apr Applied Pharma Research SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
